The data suggest that augmentation with this carbonated apatite cancellous bone cement can enhance immediate screw fixation.
Purpose: The combination of vaccines and chemotherapy holds promise for cancer therapy, but the effect of cytotoxic chemotherapy on vaccine-induced antitumor immunity is unknown. This study was conducted to assess the effects of systemic chemotherapy on ALVAC-CEA/ B7.1^induced T-cell immunity in patients with metastatic colorectal cancer. Experimental Design: Patients with metastatic colorectal cancer were treated with fluorouracil, leucovorin, and irinotecan and were also given ALVAC-CEA/B7.1 vaccine with or without tetanus toxoid adjuvant. Eligible patients were randomized to ALVAC followed by chemotherapy and booster vaccination (group 1), ALVAC and tetanus toxoid followed by chemotherapy (group 2), or chemotherapy alone followed by ALVAC in patients without disease progression (group 3). Humoral immune responses were measured by standard ELISA assay, and carcinoembryonic antigen (CEA)-specific T-cell responses were measured by IFN-g enzyme-linked immunospot assay. Results: One hundred eighteen patients were randomized to receive either ALVAC before and concomitantly with chemotherapy (n = 39), ALVAC with tetanus adjuvant before and concomitantly with chemotherapy (n = 40), or chemotherapy followed by ALVAC (n = 39). Serious adverse events were largely gastrointestinal (n = 30) and hematologic (n = 24). Overall, 42 patients (40.4%) showed objective clinical responses. All patients developed antibody responses against ALVAC, but increased anti-CEA antibody titers were detected in only three patients. Increases in CEA-specific T cells were detected in 50%, 37%, and 30% of patients in groups 1, 2, and 3, respectively. There were no differences in clinical or immune responses between the treatment groups. Conclusion: The combination of ALVAC-CEA/B7.1vaccine and systemic chemotherapy has an acceptable safety profile in patients with metastatic colorectal cancer. Systemic chemotherapy did not affect the generation of CEA-specificT-cell responses following vaccination.
Mycobacteria may cause infectious crystalline keratopathy after LASIK. The presence of crystalline keratopathy in patients that underwent LASIK must be considered an indicator of nontuberculous mycobacteria infection. Microbiologic work-up of a corneal specimen is required for the institution of appropriate therapy.
BackgroundThe purpose of this paper is to describe clinical characteristics and determine correlations between clinical outcomes and antifungal susceptibility among molecularly characterized ocular Fusarium isolates in Brazil.MethodsForty-one Fusarium isolates obtained from 41 eyes of 41 patients were retrieved from the ophthalmic microbiology laboratory at São Paulo Federal University and grown in pure culture. These isolates were genotyped and antifungal susceptibilities determined for each isolate using a broth microdilution method. The corresponding medical records were reviewed to determine clinical outcomes.ResultsThe 41 isolates were genotypically classified as Fusarium solani species complex (36 isolates, 88%), Fusarium oxysporum species complex (two isolates, 5%), Fusarium dimerum species complex (one isolate, 2%) and two isolates that did not group into any of the species complexes. Final best corrected visual acuity varied from 20/20 to light perception and was on average 20/800 (logarithm of the minimum angle of resolution (LogMAR) 1.6). A history of trauma was the most common risk factor, being present in 21 patients (51%). Therapeutic penetrating keratoplasty was necessary in 22 patients (54%). Amphotericin B had the lowest minimum inhibitory concentration for 90% of isolates (MIC90) value (2 μg/mL) and voriconazole had the highest (16 μg/mL). There was an association between a higher natamycin MIC and need for therapeutic penetrating keratoplasty (Mann–Whitney test, P < 0.005).ConclusionTrauma was the main risk factor, and therapeutic penetrating keratoplasty was necessary in 54% of patients. Amphotericin B had the lowest MIC90 (2 μg/mL) of the three antifungal agents tested. There was an association between higher natamycin MIC levels and corneal perforation, emphasizing the need for antifungal susceptibility testing and tailoring of antifungal strategies.
To describe the epidemiological and laboratory characteristics of microbial keratitis at a referral center in Brazil. Charts of all patients referred to the Ocular Microbiology Laboratory at Federal University of São Paulo (UNIFESP) from July 1975 to September 2007 were retrospectively reviewed. The following data were recorded: age, gender, involved eye, use of ocular medication, previous trauma or surgery, contact lens wear and the results of laboratory cultures. The study included 6,804 corneal cultures. The mean age was 42.1 ± 21.4 years. The male-to-female ratio was 1.5:1. Positive cultures were obtained in 3,309 (48.6%) cases. Of these, bacteria were isolated in 2,699 (39.7%), fungi in 364 (5.3%) and Acanthamoeba in 246 (3.6%) samples. Positive bacterial cultures were 2.7-fold more frequent in patients with previous use of steroids (P < 0.01), and a 30% reduction in positive bacterial cultures was observed in patients with previous use of antibiotics (P < 0.01). A total of 1,524 patients (22.4%) had a past history of ocular surgery. Contact lens wearers showed a 1.7 times greater chance of having an Acanthamoeba-positive culture (P < 0.01). Previous ocular trauma was present in 1,118 (16.4%) cases and injury caused by plants showed a 3.8 times greater chance of a positive fungal culture (P < 0.01). Bacterial organisms were identified as the most frequent agent followed by fungi and Acanthamoeba. Prescription of steroids and antibiotics prior to corneal scrapings may modify the laboratory test results. Previous corneal surgery, contact lens wear and ocular trauma have been shown to be risk factors for bacterial, Acanthamoeba and fungal keratitis, respectively.
OBJECTIVE:To determine the conjunctival bacterial flora present in patients with Stevens-Johnson syndrome.METHODS:A prospective study of the conjunctival bacterial flora was performed in 41 eyes of 22 patients with Stevens-Johnson syndrome. The information gathered included the patient's sex and age, the duration of disease, the cause of Stevens-Johnson syndrome, and treatments. Scrapings of the inferior conjunctival fornix were performed in both eyes. Fourteen days before scraping, the patients were asked to interrupt all topical medication and start using 0.5% nonpreserved methylcellulose. The microbiological evaluation included microorganism identification and determination of antibiotic sensitivity.RESULTS:Of 22 patients (41 eyes), 14 (64%) were females, and eight (36%) were males. The mean age was 33.2 years, and the mean duration of disease was 15.6 years. Visual acuity ranged from light perception to 20/25 (1.57 logMar). The treatment received by most patients consisted of tear substitutes, topical antibiotics, and contact lenses. Bacterial identification was positive in 39 eyes (95%) and negative in two eyes (5%). Gram-positive cocci accounted for 55.5% of the microorganisms, whereas gram-positive bacilli and gram-negative bacilli accounted for 19% and 25.5%, respectively.Half of the patients (54%) had multiple bacterial species in their flora, and only one bacterial species was identified in the other half. Resistant bacteria were isolated from four eyes. The antibiotic sensitivity results for the Streptococcus group showed the lowest sensitivity and the highest microbial resistance identified.CONCLUSION:Patients with Stevens-Johnson syndrome have a diverse conjunctival flora that includes many pathogenic species.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.